Biomarin Pharmaceutical IncBMRN
Price$58.44Intrinsic value$101.0973% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $101.09median of 6 methods · middle span $34-$231based on filings through 30 Jun 2026
Market Price $58.44Price as of 1 Oct 2026
Margin of Safety +73.0%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 5.0% (near-term consensus, capped) · years 2–5: 77.8%/yr (balance of the path).60.0% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 662.8%Yr 747.9%Yr 832.9%Yr 918.0%Yr 103.0%
77.8% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 1 window (5y) (limited history)-16.7%
Discount rate (cost of equity) 7.1%
Volatility vs market (adjusted beta)0.48

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetBiomarin Pharmaceutical IncBMRNHealth Care
Valuation
P/E153.8×
P/S3.7×
P/B2.0×
EV / Revenue4.7×
EV / EBITDA20.8×
Profitability
Gross margin74.6%
Operating margin16.9%
Net margin2.1%
FCF margin21.7%
Returns
ROE1.2%
ROA0.6%
ROIC0.8%
Growth
Revenue growth (YoY)19.4%
5-yr fwd EPS growth62.7%
Financial strength
Debt / Equity0.66×
Current ratio2.39×
Altman Z-Score2.0
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.